Skip to content

CNTN CNTN Proceeds From Issuance Of Public Placement

Proceeds From Issuance Of Public Placement at other companies

Immunome logo
ImmunomeIMNM
$0-100%
VAT
InnovateVATE
$0-100%
Silvaco Group, Inc. logo
Silvaco Group, Inc.SVCO
$0-100%
Phathom Pharmaceuticals, Inc. logo
Phathom Pharmaceuticals, Inc.PHAT
$121.97M
HTF
Heartflow, Inc. Common StockHTFL
$83.1M
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$68.93M

Other financials

Income statement

See full
Operating income-$36.9M-1,348%
Net income-$47.3M-1,763%
EPS (diluted)-$0.23+76.8%

Balance sheet

See full
Cash & equivalents$41.5M+3,760%
Total debt$1.4M0.0%
Total equity$469.8M+57,767%
Total assets$584.7M+35,093%

Cash flow

See full
Operating cash flow-$7.6M-184%

Valuation

See full
Market cap$217.49M+8.0%

Returns & leverage

See full
Return on equity-18%-8.6pp
Debt / equity0.3×
Current ratio37.7×+37.1×

Where this comes from

Reported directly by CNTN in its filing.

Tagged under the XBRL concept CNTN:ProceedsFromIssuanceOfPublicPlacement.

The official record: CNTN’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about CNTN's proceeds from issuance of public placement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CNTN's proceeds from issuance of public placement?
CNTN (CNTN) reported proceeds from issuance of public placement of $54.89M in Q1 2026.
How has CNTN's proceeds from issuance of public placement changed year-over-year?
CNTN's proceeds from issuance of public placement increased by 2997.0% year-over-year, from $1.77M to $54.89M.
What does proceeds from issuance of public placement mean?
Represents the cash proceeds generated from the sale of securities to the general public. This metric serves as a measure of the company's access to broader capital markets to support its long-term strategic initiatives.